Track Takeda Pharmaceutical Company Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Takeda Pharmaceutical Company Limited TAK · Stock Open Takeda Pharmaceutical Company Limited in new tab

21.43 USD
P/E
296.79
EPS
0.07
Yield
2.93%
Safety Score
62
P/B
1.42
ROE
0.56
Beta
0.08
Target Price
22.92 USD
Takeda Pharmaceutical Company Limited logo

Takeda Pharmaceutical Company Limited

🧾 Earnings Recap – Q4 2025

Shares in Takeda edged up modestly by 1.3%, reflecting a steady fiscal year 2025 performance that balanced ongoing LOE headwinds and pipeline progress, without clear market conviction on near-term growth catalysts.

  • Core revenue was approximately JPY 4.5 trillion, partly pressured by loss of exclusivity in mature products.
  • Core operating profit reached around JPY 1.17 trillion, supported by robust cost management and efficiency measures.
  • Takeda delivered positive Phase III data for multiple late-stage assets, including oveporexton, rusfertide, and zasocitinib, setting the stage for potential regulatory approvals and launches in 2026.
  • The pipeline was further strengthened with Phase III starts for elritercept and mezagitamab, and strategic oncology partnerships expanded future growth opportunities.
  • Management emphasized disciplined commercial execution alongside innovation, signaling focus on upcoming launches amid a pivot to an evolved operating model to drive efficiency and sustainability.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 4, 2027
P/E296.79
EPS0.07
Book Value14.68
Price to Book1.42
Debt/Equity72.23
% Insiders0.112%
Growth
Revenue Growth0.07%
Earnings Growth-0.10%
Estimates
Forward P/E39.20
Forward EPS0.53
Target Mean Price22.92
Dividend
Dividend Yield2.93%
Annual dividends101.00 USD
Ex-Div. DateSept. 29, 2026
Payout82.01%
5y avg Yield4.64%

DCF valuation

Model fair value for Takeda Pharmaceutical Company Limited (TAK)
Result
Sign in to run the valuation for TAK.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
3 analysts · consensus Strong buy · mean target 22.92 USD (low 20.90, high 25.87) · as of 10 Nov 2026
Low 20.90
Mean 22.92
High 25.87
Price 21.43
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Takeda Pharmaceutical Company Limited Logo Takeda Pharmaceutical Company Limited Analysis (TAK)

Japan Health Care Official Website Stock

Is Takeda Pharmaceutical Company Limited a good investment? Takeda Pharmaceutical Company Limited (TAK) is currently trading at 21.43 USD. Market analysts have a consensus price target of 22.92 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 296.79. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Takeda Pharmaceutical Company Limited is expected to release its next earnings report on Feb. 4, 2027. The market consensus estimate for Forward EPS is 0.53.

For income investors, Takeda Pharmaceutical Company Limited pays a dividend yield of 2.93%. With a payout ratio of 82%, the dividend appears to be under pressure.

Investor FAQ

Does Takeda Pharmaceutical Company Limited pay a dividend?

Yes, it pays an annual dividend of 101.00 USD (2.93% yield).

What asset class is Takeda Pharmaceutical Company Limited?

Takeda Pharmaceutical Company Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 4, 2027. The company currently has a trailing EPS of 0.07.

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Exchange Ticker
NYQ (United States) TAK
Trades
Dividend Yield
2.93%
5y avg 4.64%
Annual Dividends
101.00USD
Next Ex. Div Date
Sept. 29, 2026
Payout Ratio
82.01%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.68 USD
Sept. 29, 2027 (estimated) 0.3970
July 12, 2027 (estimated) 0.2823
▸2026
1.01 USD
Dec. 11, 2026 (estimated) 0.3007
Sept. 29, 2026 0.3970
July 6, 2026 0.3083
▸2025
0.60 USD
Dec. 11, 2025 0.3214
July 7, 2025 0.2760
▸2024
0.62 USD
Dec. 12, 2024 0.3260
July 8, 2024 0.2920
▸2023
0.63 USD
Dec. 11, 2023 0.3191
July 10, 2023 0.3100
▸2022
0.66 USD
Dec. 12, 2022 0.3296
July 11, 2022 0.3301
▸2021
0.80 USD
Dec. 13, 2021 0.3969
July 12, 2021 0.4066
▸2020
0.85 USD
Dec. 11, 2020 0.4305
July 6, 2020 0.4191
▸2019
0.77 USD
Dec. 12, 2019 0.4111
June 28, 2019 0.3552
▸2018
0.80 USD
Dec. 13, 2018 0.3955
July 9, 2018 0.4064
▸2017
0.80 USD
Dec. 11, 2017 0.3995
July 10, 2017 0.3989
▸2016
0.83 USD
Dec. 12, 2016 0.3924
July 11, 2016 0.4371
▸2015
0.73 USD
Dec. 11, 2015 0.3653
July 9, 2015 0.3653
▸2014
0.82 USD
Dec. 11, 2014 0.3783
July 10, 2014 0.4437
▸2013
0.89 USD
Dec. 12, 2013 0.4370
July 8, 2013 0.4571
▸2012
1.11 USD
Dec. 13, 2012 0.5460
July 9, 2012 0.5638
▸2011
1.13 USD
Dec. 12, 2011 0.5786
July 7, 2011 0.5558
▸2010
0.53 USD
Dec. 13, 2010 0.5332
▸2009
1.00 USD
Dec. 15, 2009 0.5178
July 14, 2009 0.4818
▸2008
0.47 USD
Dec. 16, 2008 0.4681
Upcoming Dividends
Name Payment Date Status Amount
Takeda Pharmaceutical Company Limited Sep 29, 2026 0.397 USD
Takeda Pharmaceutical Company Limited Jul 06, 2026 0.30827 USD
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion